OUR VISION
We are building a leading, next generation precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology
KEY FOCUS AREA
Focus on Oncology
We are united in the mission:
ACT against pancreatic cancer
Latest company news:
-
Business Norway article about ultrasound in healthcare
-
Minutes from Annual General meeting 2024
The minutes from the Annual General meeting are available
-
Notice of Annual General Meeting 2024
Notice for the Annual General meeting has been published
-
EXACT-Tx publishes 2023 Annual Report
The Annnual Report for 2023 was published on April 18, 2024
Our pipeline
Our technology
The Key differentiation of ACT® is:
ACT® has a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue, without damaging the cells within the capillary walls; unlike sonoporation, ACT® does not create holes in the epithelial cell membranes of the capillary wall.
With ACT®, the drug can reach IOO microns which is 10 layers of cells away from capillary with an ongoing pump effect that lasts for minutes.
Reproducible and signifcant uptake through targeted delivery into tumours and across the blood brain barrier (BBB).
A very strong toxicology package:
including most recently, in relation to BBB opening where no extravasation of red blood cells was observed throughout the ACT® procedure in a preclinical rodent model.
Uses a bespoke dual frequency transducer with a standard ultrasound scanner to activate and enhance the clusters at the target tumour site. Compatible with existing ultrasound systems widely available in clinics/hospitals worldwide.
No drug reformulation required.
ACT® relies on ultrasound settings well within safe and approved ranges.
State of the art navigation system in development to ensure ACT® is delivered accurately at a targeted site